EchoGo Pro
FDA 510(k) K201555 · Ultromics, Ltd.
510(k) numberK201555
Submission
- Device name
- EchoGo Pro
- Applicant
- Ultromics, Ltd.
Oxford, GB - Received
- June 10, 2020
- Decision date
- December 18, 2020
- Decision
- Substantially Equivalent (SESE)
- Type
- Traditional 510(k)
- Summary
- 510(k) summary available from FDA
Other 510(k)s with product code POK
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K253884 | Koios DS (3.8)POK · Traditional | Koios Medical, Inc. | 07/02/2026SE |
| K261519 | Sonio SuspectPOK · Special | Sonio | 06/04/2026SE |
| K254161 | Automated Aortic Stenosis Software (AutoAS)POK · Traditional | GE Medical Systems Ultrasound & Primary Care… | 03/27/2026SE |
| K251769 | RevealAI-LungPOK · Traditional | Precision Medical Ventures, Inc. Dba Revealdx | 01/30/2026SE |
| K252294 | Fetal EchoScan (v1.2)POK · Traditional | Brightheart | 12/08/2025SE |
| K250221 | StrokeSENS ASPECTS Software ApplicationPOK · Traditional | Circle Cardiovascular Imaging, Inc. | 07/01/2025SE |
| K251071 | Fetal EchoScan (v1.1)POK · Special | Brightheart | 05/02/2025SE |
| K243614 | Sonio SuspectPOK · Traditional | Sonio | 02/21/2025SE |
| K243294 | Brainomix 360 e-ASPECTSPOK · Traditional | Brainomix Limited | 02/14/2025SE |
| K242130 | Koios DSPOK · Traditional | Koios Medical, Inc. | 11/15/2024SE |
More from Koios Medical, Inc.
| 510(k) | Device | Decision |
|---|---|---|
| K240860 | EchoGo Amyloidosis (1.0)SDJ · Traditional | 11/15/2024SE |
| K240013 | EchoGo Heart Failure (2.0)QUO · Traditional | 09/23/2024SE |
| K222463 | EchoGo Heart FailureQUO · Traditional | 11/23/2022SE |
| K213275 | EchoGo Core (2.0)QIH · Traditional | 12/20/2021SE |
| K191171 | EchoGo CoreQIH · Traditional | 11/13/2019SE |
Questions and answers
When was EchoGo Pro cleared by the FDA?
EchoGo Pro (K201555) received a 510(k) decision of Substantially Equivalent on December 18, 2020, 191 days after the submission was received.
What is the product code of K201555?
The FDA product code is POK – Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer, a Class II (moderate risk) device regulated under 21 CFR 892.2060.